# Chemopreventive Action of Mesalazine on Colorectal Cancer: a Pilot Study for an "in Vivo" Evaluation of the Molecular Effects on β-catenin Signaling Pathway.

> **NCT02077777** · PHASE2 · COMPLETED · sponsor: **SOFAR S.p.A.** · enrollment: 21 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Mesalazine

## Key facts

- **NCT ID:** NCT02077777
- **Lead sponsor:** SOFAR S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2016-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02077777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02077777, "Chemopreventive Action of Mesalazine on Colorectal Cancer: a Pilot Study for an "in Vivo" Evaluation of the Molecular Effects on β-catenin Signaling Pathway.". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02077777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*